• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Medicines

Medicines

  1. The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO -216 Modified Key Lipid Parameters and Was Well-Tolerated in Healthy and Coronary Artery Disease (CAD) Patients

    The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO -216 Modified Key Lipid Parameters and Was Well-Tolerated in Healthy and Coronary Artery Disease (CAD) Patients

  2. The Medicines Company to Participate in Credit Suisse Healthcare Conference

    The Medicines Company to Participate in Credit Suisse Healthcare Conference

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.